Xenogeneic Graft-Versus-Host Disease in Humanized NSG and NSG-HLA-A2/HHD Mice

Despite the increasing use of humanized mouse models to study new approaches of graft-versus-host disease (GVHD) prevention, the pathogenesis of xenogeneic GVHD (xGVHD) in these models remains misunderstood. The aim of this study is to describe this pathogenesis in NOD/LtSz-PrkdcscidIL2rγtm1Wjl (NSG) mice infused with human PBMCs and to assess the impact of the expression of HLA-A0201 by NSG mice cells (NSG-HLA-A2/HHD mice) on xGVHD and graft-versus-leukemia (GvL) effects, by taking advantage of next-generation technologies. We found that T cells recovered from NSG mice after transplantation had upregulated expression of genes involved in cell proliferation, as well as in TCR, co-stimulatory, IL-2/STAT5, mTOR and Aurora kinase A pathways. T cells had mainly an effector memory or an effector phenotype and exhibited a Th1/Tc1-skewed differentiation. TCRβ repertoire diversity was markedly lower both in the spleen and lungs (a xGVHD target organ) than at infusion. There was no correlation between the frequencies of specific clonotypes at baseline and in transplanted mice. Finally, expression of HLA-A0201 by NSG mice led to more severe xGVHD and enhanced GvL effects toward HLA-A2+ leukemic cells. Altogether our data demonstrate that the pathogenesis of xGVHD shares important features with human GVHD and that NSG-HLA-A2/HHD mice could serve as better model to study GVHD and GvL effects.

[1]  D. Greiner,et al.  Human peripheral blood leucocyte non‐obese diabetic‐severe combined immunodeficiency interleukin‐2 receptor gamma chain gene mouse model of xenogeneic graft‐versus‐host‐like disease and the role of host major histocompatibility complex , 2009, Clinical and experimental immunology.

[2]  F. Baron,et al.  Impact of bone marrow-derived mesenchymal stromal cells on experimental xenogeneic graft-versus-host disease. , 2013, Cytotherapy.

[3]  D. Greiner,et al.  Humanized Mouse Models of Clinical Disease. , 2017, Annual review of pathology.

[4]  A. Gratwohl,et al.  Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  R. Woodland,et al.  A new Hu-PBL model for the study of human islet alloreactivity based on NOD-scid mice bearing a targeted mutation in the IL-2 receptor gamma chain gene. , 2008, Clinical immunology.

[6]  B. Falini,et al.  HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. , 2014, Blood.

[7]  André F. Rendeiro,et al.  Pooled CRISPR screening with single-cell transcriptome read-out , 2017, Nature Methods.

[8]  C. Haase,et al.  Human T cells depend on functional calcineurin, tumour necrosis factor‐α and CD80/CD86 for expansion and activation in mice , 2013, Clinical and experimental immunology.

[9]  Shigeru Tsuchiya,et al.  Establishment and characterization of a human acute monocytic leukemia cell line (THP‐1) , 1980, International journal of cancer.

[10]  B. Blanco,et al.  Targeting of PI3K/AKT/mTOR pathway to inhibit T cell activation and prevent graft-versus-host disease development , 2016, Journal of Hematology & Oncology.

[11]  A. Barrett,et al.  Review Articles (434 articles) , 2003 .

[12]  M. Sorror,et al.  Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  B. Blazar,et al.  Acute graft-versus-host disease: from the bench to the bedside. , 2005, Blood.

[14]  B. Blazar,et al.  Pathogenesis of acute graft‐versus‐host disease: from intestinal microbiota alterations to donor T cell activation , 2016, British journal of haematology.

[15]  E. Holler,et al.  Pathophysiology of GvHD and Other HSCT-Related Major Complications , 2017, Front. Immunol..

[16]  Huan Yang,et al.  Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining Treg and antitumor CTL function , 2017, Science Translational Medicine.

[17]  M. Mohty,et al.  Interleukin-22 in Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation , 2016, Front. Immunol..

[18]  P. Delvenne,et al.  Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease , 2016, Journal of Hematology & Oncology.

[19]  F. Baron,et al.  Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects , 2017, Oncoimmunology.

[20]  P. Delvenne,et al.  Infusion of clinical‐grade enriched regulatory T cells delays experimental xenogeneic graft‐versus‐host disease , 2013, Transfusion.

[21]  J. Falkenburg,et al.  HLA class II upregulation during viral infection leads to HLA-DP-directed graft-versus-host disease after CD4+ donor lymphocyte infusion. , 2013, Blood.

[22]  Thomas M. Schmitt,et al.  Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen. , 2012, Blood.

[23]  P. Delvenne,et al.  Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo , 2015, Science Translational Medicine.

[24]  B. Bonnotte,et al.  Human monocyte-derived suppressor cells control graft-versus-host disease by inducing regulatory forkhead box protein 3-positive CD8+ T lymphocytes. , 2015, The Journal of allergy and clinical immunology.

[25]  L. Tian,et al.  Engraftment of severe combined immune deficient mice receiving allogeneic bone marrow via In utero or postnatal transfer. , 1998, Blood.

[26]  B. Blazar,et al.  Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy. , 2017, The New England journal of medicine.

[27]  R. Zeiser,et al.  Acute Graft-versus-Host Disease: Novel Biological Insights. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[28]  D. Olive,et al.  Targeting the Human T-Cell Inducible COStimulator Molecule with a Monoclonal Antibody Prevents Graft-vs-Host Disease and Preserves Graft vs Leukemia in a Xenograft Murine Model , 2017, Front. Immunol..

[29]  F. Baron,et al.  Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Following Flu-TBI versus TLI-ATG Conditioning , 2015, Clinical Cancer Research.

[30]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[31]  Bruce R. Blazar,et al.  Massive ex Vivo Expansion of Human Natural Regulatory T Cells (Tregs) with Minimal Loss of in Vivo Functional Activity , 2011, Science Translational Medicine.

[32]  F. Bach,et al.  ALLOGENEIC AND XENOGENEIC RESPONSE IN MIXED LEUKOCYTE CULTURES , 1972, The Journal of experimental medicine.

[33]  Marianna Zahurak,et al.  Aldehyde Dehydrogenase Expression Drives Human Regulatory T Cell Resistance to Posttransplantation Cyclophosphamide , 2013, Science Translational Medicine.

[34]  J. Magenau,et al.  Danger Signals and Graft-versus-host Disease: Current Understanding and Future Perspectives , 2016, Front. Immunol..

[35]  Clare L. Bennett,et al.  Unraveling the Mechanisms of Cutaneous Graft-Versus-Host Disease , 2018, Front. Immunol..

[36]  R. Dressel,et al.  The Role of Animal Models in the Study of Hematopoietic Stem Cell Transplantation and GvHD: A Historical Overview , 2016, Front. Immunol..

[37]  C. Ziegler,et al.  Transcriptome analysis of GVHD reveals aurora kinase A as a targetable pathway for disease prevention , 2015, Science Translational Medicine.

[38]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[39]  J. Gribben,et al.  Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production , 1993, The Journal of experimental medicine.

[40]  Tinghua Cao,et al.  RORγt and RORα signature genes in human Th17 cells , 2017, PloS one.

[41]  Satoshi Tanaka,et al.  Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2rγnull humanized mice , 2010, Proceedings of the National Academy of Sciences.

[42]  R. Storb,et al.  Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review , 2004, Springer Seminars in Immunopathology.

[43]  S. Riddell,et al.  Molecules and mechanisms of the graft-versus-leukaemia effect , 2004, Nature Reviews Cancer.

[44]  F. Baron,et al.  Validation of a multicolor staining to monitor phosphoSTAT5 levels in regulatory T-cell subsets , 2015, Oncotarget.

[45]  B. Salomon,et al.  Control of GVHD by regulatory T cells depends on TNF produced by T cells and TNFR2 expressed by regulatory T cells. , 2016, Blood.

[46]  S. Rosenberg.  Of mice, not men: no evidence for graft-versus-host disease in humans receiving T-cell receptor-transduced autologous T cells. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[47]  Clare L. Bennett,et al.  G-CSF mobilizes CD34+ regulatory monocytes that inhibit graft-versus-host disease , 2015, Science Translational Medicine.

[48]  T. Manser,et al.  Evaluation of the efficiency of human immune system reconstitution in NSG mice and NSG mice containing a human HLA.A2 transgene using hematopoietic stem cells purified from different sources. , 2015, Journal of immunological methods.

[49]  F. Lemonnier,et al.  HLA-A2.1–restricted Education and Cytolytic Activity of CD8+ T Lymphocytes from β2 Microglobulin (β2m) HLA-A2.1 Monochain Transgenic H-2Db β2m Double Knockout Mice , 1997, The Journal of experimental medicine.

[50]  F. Baron,et al.  Evidence for neo-generation of T cells by the thymus after non-myeloablative conditioning , 2008, Haematologica.

[51]  A. Dickinson,et al.  Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia , 2017, Front. Immunol..